CAJ | 학술논문

目的:观察厄贝沙坦联合肾炎康复片治疗慢性肾脏病的疗效.方法:慢性肾脏病患者43例随机分为两组,厄贝沙坦组(21例)应用厄贝沙坦150mg,1次/d,联合治疗组(22例)在上述治疗的基础上加用肾炎康复片5粒,3次/d.治疗时间为3个月,观察临床症状,血肌酐、血钾、24h 尿蛋白定量.结果:治疗3个月后比较,厄贝沙坦组与厄贝沙坦联合肾炎康复片,两组治疗前比较,收缩压,舒张压,肌酐,血钾,蛋白尿,均 P>0.05,无显著性差异.厄贝沙坦组治疗前后,收缩压、舒张压、蛋白尿, P<0.05,有显著性差异;肌酐、血钾,P>0.05,无显著性差异.联合组,治疗前后,收缩压、舒张压,有显著性差异,P<0.05;肌酐、血钾,P>0.05,无显著性差异;蛋白尿,P<0.05,有显著性差异.两组治疗后,蛋白尿,P<0.05,有显著性差异,联合组较厄贝沙坦组下降.结论:单用厄贝沙坦及联合应用厄贝沙坦和肾炎康复片均能减少尿蛋白,合用肾炎康复片疗效更显著.
목적:관찰액패사탄연합신염강복편치료만성신장병적료효.방법:만성신장병환자43례수궤분위량조,액패사탄조(21례)응용액패사탄150mg,1차/d,연합치료조(22례)재상술치료적기출상가용신염강복편5립,3차/d.치료시간위3개월,관찰림상증상,혈기항、혈갑、24h 뇨단백정량.결과:치료3개월후비교,액패사탄조여액패사탄연합신염강복편,량조치료전비교,수축압,서장압,기항,혈갑,단백뇨,균 P>0.05,무현저성차이.액패사탄조치료전후,수축압、서장압、단백뇨, P<0.05,유현저성차이;기항、혈갑,P>0.05,무현저성차이.연합조,치료전후,수축압、서장압,유현저성차이,P<0.05;기항、혈갑,P>0.05,무현저성차이;단백뇨,P<0.05,유현저성차이.량조치료후,단백뇨,P<0.05,유현저성차이,연합조교액패사탄조하강.결론:단용액패사탄급연합응용액패사탄화신염강복편균능감소뇨단백,합용신염강복편료효경현저.
Objective: To observe the efficacy of irbesartan combined with Shenyan Kangfu tablets in treating chronic kidney diseases. Methods: 43 patients with IgA nephropathy were randomly divided into two groups, 21 patients in the irbesartan treated group and 22 patients in the integrated treated group. The irbesartan treated group was given 150mg irbesartan once a day, while the integrated treated group was given 5 pills of Shenyan Kangfu tablets more three times a day. The treatment lasted for 3 months. The clinical symptoms and the contents of serum creatinine, potassium and proteinuria in 24 hours were observed. Results: No marked differences were detected in the contractive pressure, diastolic pressure and the contents of serum creatinine, potassium and proteinuria before and after treatment and between the two groups (P>0.05). In the integrated treated group, significant differences were detected in the contractive pressure, the diastolic pressure and the proteinuria before and after treatment (P<0.05), while no significant differences were detected in the contents of serum creatinine and potassium (P>0.05). The proteinuria situation in the integrated treated group improved better than that in the irbesartan treated group, with significant differences (P<0.05). Conclusion: Single application of irbesartan and integrated use of Irbesartan and Shenyan Kangfu tablet both improved the proteinuria symptom. And the integrated treated group had better effect.